Surgical treatment of benign prostatic hyperplasia: Thulium enucleation versus single-port transvesical robotic simple prostatectomy.
Susan Talamini, Andrew Lai, Cassandra Palmer...
https://pubmed.ncbi.nlm.nih.gov/37636211/Actively Recruiting
Led by University of Illinois at Chicago · Updated on 2024-05-16
116
Participants Needed
1
Research Sites
30 weeks
Total Duration
This research aims to compare two surgical treatments for benign prostatic hyperplasia BPH in men who experience lower urinary tract symptoms or bladder outlet obstruction after non-surgical treatments have not worked. The trial evaluates the outcomes of a newer single port robotic simple prostatectomy using the da Vinci platform against thulium laser enucleation of the prostate. Both procedures are recommended for larger prostate sizes and are performed to address urinary symptoms related to BPH. Participants will be randomly assigned to receive either the single port robotic prostatectomy, which removes the whole prostate through a small incision using robotic assistance, or laser enucleation, which removes prostate tissue using laser technology while preserving the prostate capsule. This study will measure surgical parameters like operative time, blood loss, and hospital stay, as well as post-surgical complications and urinary function outcomes. The trial also assesses quality of life and sexual health before and seven months after surgery. During the study, participants will undergo evaluations including questionnaires about urinary symptoms, sexual health, and quality of life, as well as tests measuring urinary flow rate and residual urine volume. Researchers will track surgical complications and any incidental findings of cancer. The trials findings aim to help guide patients and doctors in choosing the best surgical option for BPH. The total participation duration includes assessments before and seven months after the procedure, with monitoring during and immediately after surgery.
CONDITIONS
Prostate Single Port & Laser Enucleation Comparison Trial
R
Ruben Sauer, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Illinois at Chicago
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Single Port Robotic Prostatectomy | Laser Enucleation of the Prostate |
|---|---|---|
| What it is | Minimally invasive robotic surgery that removes the entire prostate through a single small incision using a robotic system. | Laser-based operation that cores out and removes prostate tissue in 'chips', while leaving the outer covering (capsule) of the prostate intact. |
| Role in trial | Assigned as one of two surgical options for randomized comparison in adults with benign prostatic hyperplasia not responding to medications. | Assigned as the alternative surgical procedure for direct comparison in the same eligible patient group. |
| Primary use | Treatment of moderate-to-severe lower urinary tract symptoms caused by an enlarged prostate (benign prostatic hyperplasia) when medication fails. | Also used to relieve symptoms of benign prostatic hyperplasia when medications have not worked. |
| How the procedure is performed | Surgical instruments and a camera are inserted through a single small abdominal incision. The entire prostate is removed using robotic control. | A specialized laser is used endoscopically to core out and remove sections (chips) of the prostate through the urinary tract, leaving the prostate's capsule. |
| Evidence status | Effectiveness and safety are under further evaluation within randomized trials and in published cohort comparisons to laser enucleation. No definitive superiority has been established. | Laser enucleation has demonstrated efficacy in randomized and multi-center comparisons, with outcome data for urinary function and symptom improvement. No clear absolute advantage over robotic simple prostatectomy is established. |
| Important limitations | Single port robotic surgery requires specialized training and equipment, may involve longer operative time in some settings, and long-term data are still developing. | Laser enucleation can require a steep learning curve for surgeons, specialized laser equipment, and may result in different postoperative complications. The comparative benefit over robotic surgery is not fully settled. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 30 days from surgery to discharge
Participants undergo either single port robotic simple prostatectomy or laser enucleation of the prostate for treatment of benign prostatic hyperplasia. Perioperative parameters such as operative time, blood loss, and hospital stay are monitored.
1 surgery visit and hospital stay up to 30 days
Duration - 7 months after surgery
Participants are assessed for functional outcomes including urinary symptoms, urinary flow rate, sexual health, and quality of life. Additional monitoring for incidental cancer occurs 2 weeks after surgery.
Visits before surgery, at 2 weeks post-surgery, and follow-up visits up to 7 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Susan Talamini, Andrew Lai, Cassandra Palmer...
https://pubmed.ncbi.nlm.nih.gov/37636211/Alfredo Maria Bove, Aldo Brassetti, Mario Ochoa...
https://pubmed.ncbi.nlm.nih.gov/37483855/University of Illinois at Chicago
Lead Sponsor